Last reviewed · How we verify
NCT03879382
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
Phase 1 trial testing anti-CD19/BCMA CAR-T cells in POMES Syndrome in 10 participants. Status unknown.
30 August 2020
Quick facts
| Lead sponsor | Hrain Biotechnology Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 27 February 2019 |
| Primary completion | 30 August 2020 |
| Estimated completion | 30 May 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- anti-CD19/BCMA CAR-T cells — full drug profile →
- Fludarabine (FLUDARABINE) — full drug profile →
- Cyclophosphamide (cyclophosphamide) — full drug profile →
Conditions studied
- POMES Syndrome — all drugs for POMES Syndrome →
- Relapsed and Refractory POMES Syndrome — all drugs for Relapsed and Refractory POMES Syndrome →
Sponsor
Hrain Biotechnology Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with POMES Syndrome or Relapsed and Refractory POMES Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES Syndrome.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
Andrea AE, Chiron A, Mallah S, Bessoles S, et al · · 2022 · cited 48× · PMID 35211124 · DOI 10.3389/fimmu.2022.830292 -
Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy.
Zhu B, Yin H, Zhang D, Zhang M, et al · · 2024 · cited 21× · PMID 38605087 · DOI 10.1038/s41423-024-01153-x -
Multi-targeted immunotherapeutics to treat B cell malignancies.
Gambles MT, Yang J, Kopeček J. · · 2023 · cited 8× · PMID 37121515 · DOI 10.1016/j.jconrel.2023.04.048
Verify or expand the search:
- PubMed search for NCT03879382
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hrain Biotechnology Co., Ltd. trials
Trials by the same sponsor.
- NCT06045091 — To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL · EARLY_PHASE1 · recruiting
- NCT05651191 — To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL · EARLY_PHASE1 · unknown
- NCT05651178 — Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients · EARLY_PHASE1 · recruiting
- NCT05594797 — Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM · Phase 2 · recruiting
- NCT05223686 — To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03879382 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hrain Biotechnology Co., Ltd.
- Last refreshed: 6 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03879382.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing